The acquisitions are part of Steris’s efforts to its healthcare segment and provide niche services to customers, according to a company statement.
BILLERICA, Mass.–(BUSINESS WIRE)–Bruker Corporation today announced the signing of a purchase agreement
to acquire Center for Tribology, Inc. (CETR) for an undisclosed amount.
CETR, a privately held corporation located in Silicon Valley in
Campbell, CA, is projected to have calendar year 2011 revenue greater
than $10 million and EBITDA greater than $2 million. The transaction is
expected to close at the end of the third quarter of 2011, subject to
customary closing conditions. After the closing, Bruker intends to
continue to operate CETR in Silicon Valley and to integrate its business
management, operations, research and development, sales and support with
The deal, first announced Dec. 13, 2010, was beset by several delays in clearing anti-trust hurdles in the European Union and the U.S.
Laser-based lab equipment maker Hamilton Thorne Inc. (CVE:HTL) derives a major part of its revenues from the life sciences R&D market. CEO Meg Spencer says that requires the company to surf the leading edge of several life science research waves, including stem cells and regenerative medicine.
The Beverly, Mass.-based company looks to help solve some of the problems scientists encounter as they develop their research on stem cells into regenerative medicine techniques. Those often involve the growth of millions — or even billions — of cells, so anything that can accelerate or automate that process is vital to innovation in the space.
Thermo Fisher officials released a statement today saying the deadline for the $2.2 billion deal would be pushed back to May 13 to satisfy the remaining anti-trust hurdles in the European Union.
Thermo Fisher Scientific Inc. (NYSE:TMO) yesterday revealed plans for its third expansion project in China within the last 12 months.
The company intends to open a laboratory instruments manufacturing plant in the Suzhou municipality in early 2012.
A dip in fourth-quarter net income is starting to catch up with Harvard Bioscience (NSDQ:HBIO) today, with share prices sliding to reverse a modest rally earlier in the day.
HBIO shares were down 6 cents to $4.32 each by roughly 2 p.m. The lab instruments maker this morning reported $2.2 million in fourth-quarter profits on $29.5 million in sales — beating the revenue estimate of the lone analyst tracking the company — and a 6.8 percent increase from year-ago revenues. Earnings per share were 8 cents.
Recently acquired Millipore pumped nearly $900 million in additional revenues into Merck Group KGaA (XETRA:MRK) during the second half of 2010, including a $465 million, fourth-quarter contribution.
The Waltham, Mass.-based lab instruments maker plans to pay about $2.1 billion in cash for Dionex, or $118.50 per share, a 21 percent premium over DNEX’s last closing price of $98.16.
Caliper Life Sciences Inc. (NSDQ:CALP) agreed to buy Woburn, Mass.-based Cambridge Research & Instrumentation Inc.
The $20 million deal will see Caliper acquire all of CRi’s outstanding equity securities in exchange for common stock valued at about $10.5 million and $7.5 million in cash plus the assumption of $2 million in debt.